Effect of resveratrol in gestational diabetes mellitus and its complications.

The incidence rate of diabetes in pregnancy is about 20%, and diabetes in pregnancy will have a long-term impact on the metabolic health of mothers and their offspring. Mothers may have elevated blood glucose, which may lead to blood pressure disease, kidney disease, decreased resistance and secondary infection during pregnancy. The offspring may suffer from abnormal embryonic development, intrauterine growth restriction, obesity, autism, and other adverse consequences. Resveratrol (RSV) is a natural polyphenol compound, which is found in more than 70 plant species and their products, such as Polygonum cuspidatum, seeds of grapes, peanuts, blueberries, bilberries, and cranberries. Previous studies have shown that RSV has a potential beneficial effect on complex pregnancy, including improving the indicators of diabetes and pregnancy diabetes syndrome. This article has reviewed the molecular targets and signaling pathways of RSV, including AMP-activated protein kinase, mitogen-activated protein kinases, silent information regulator sirtuin 1, miR-23a-3p, reactive oxygen species, potassium channels and CX3C chemokine ligand 1, and the effect of RSV on gestational diabetes mellitus (GDM) and its complications. RSV improves the indicators of GDM by improving glucose metabolism and insulin tolerance, regulating blood lipids and plasma adipokines, and modulating embryonic oxidative stress and apoptosis. Furthermore, RSV can ameliorate the GDM complications by reducing oxidative stress, reducing the effects on placentation, reducing the adverse effects on embryonic development, reducing offspring's healthy risk, and so on. Thus, this review is of great significance for providing more options and possibilities for further research on medication of gestational diabetes.

Identification of the hydroxylated derivatives of bufalin: phase I metabolites in rats.

Bufalin was a typical bioactive bufadienolide, existed in the traditional Chinese medicine Chan Su with the high content of 1-5%. The in vivo metabolites (1-5) of bufalin were prepared by various chromatographic techniques from the bile samples of SD rats, which were administrated with bufalin orally. Their structures were determined on the basis of the widely spectroscopic data, including HRESIMS, 1D-, and 2D NMR. And 1-3, 5 were new compounds. In the in vitro cytotoxicity assay, metabolites (1-5) showed weaker cytotoxic effects than bufalin against human cancer cell lines A549 and H1299, which indicated that the metabolism was a significant pathway for the detoxification of bufalin. Structures analyses indicated that metabolites 1-5 were hydroxylated derivatives of bufalin. This study suggested that Phase I metabolism catalyzed by CYP450 enzymes was one of the metabolic ways of bufalin, which may promote the excretion of bufalin.

Biotransformation of resibufogenin by Actinomucor elegans.

Resibufogenin (RB), a major bioactive bufadienolide, has the potential anticancer activity. In the present work, biotransformation of RB by Actinomucor elegans AS 3.2778 yielded five products, namely 3-oxo-resibufogenin (1), 3-epi-resibufogenin (2), 3-epi-12-oxo-hydroxylresibufogenin (3), 3α-acetoxy-15α-hydroxylbufalin (4), and 3-epi-12α-hydroxylresibufogenin (5), respectively. Among them, metabolites 3 and 4 are previously unreported. The chemical structures of metabolites 1-5 were fully elucidated on the basis of 2D NMR and HR-MS. The highly stereo- and regio-specific isomerization, hydroxylation, and esterification reactions were observed in the biotransformation process of RB by A. elegans. Their cytotoxicities against A549 and H1299 cells were evaluated.

Microbial transformation of resibufogenin by Curvularia lunata AS 3.4381.

In this paper, the microbial transformation of resibufogenin by Curvularia lunata AS 3.4381 was investigated, and four transformed products were isolated and characterized as 3-epi-resibufogenin (2), 12α-hydroxy-3-epi-resibufogenin (3), 12-oxo-16ß-hydroxy-3-epi-resibufogenin (4), and 12ß,15-epoxy-3-epi-bufalin-14,15-ene (5). Among them, 4 and 5 are new compounds, and isomerization, hydroxylation, and oxidation reactions in microbial transformation process were observed. Additionally, the cytotoxicities of transformed products (2-5) were also investigated.

Microbial transformation of Norkurarinone by Cunninghamella blakesleana AS 3.970.

In this paper, microbial transformation of norkurarinone (1) by Cunninghamella blakesleana AS 3.970 was investigated and seven transformed products were isolated and characterized as kurarinone (2), 4″,5″-dihydroxykurarinone (3), 6″-hydroxyl-2'-methoxyl-norkurarinone 7-O-ß-d-glucoside (4), 6″-hydroxyl-norkurarinone 4'-O-ß-d-glucoside (5), 4″,5″-dihydroxynorkurarinone (6), 7-methoxyl-norkurarinone (7), and 7-methoxyl-4″,5″-dihydroxynorkurarinone (8), respectively. Among them, 3-5 are new compounds, and the glycosylation reaction in microbial transformation process was reported rarely. In addition, the cytotoxicities of transformed products (1-8) were also investigated.

Novel microbial transformation of resibufogenin by Fusarium solani.

In this paper, microbial transformation of resibufogenin by Fusarium solani AS 3.1829 was investigated, and five transformed products were isolated and identified as 3-ketone-resibufogenin (2), 3-one-cyclic 3-(1,2-dimethyl-1,2-ethanediylacetal)-resibufogenin (3), 3-dimethoxyl-resibufogenin (4), 3-epi-resibufogenin (5), and 3-epi-15α-hydroxy-7ßH-bufalin (6), respectively. Among them, 3, 4, and 6 are new compounds, and the rare double oxidization of C-3 was reported. In addition, the cytotoxicities of transformed products were also investigated.

Novel microbial transformation of resibufogenin by Absidia coerules.

Resibufogenin is one of the major active components of the Chinese medicine ChanSu. In this paper, microbial transformation of resibufogenin by Absidia coerules AS 3.3382 was investigated and five metabolites were isolated and identified as 5beta-hydroxy-resibufogenin (2), 3-epi-resibufogenin (3), 3alpha-hydroxy-15-oxo-14alphaH-bufa-20, 22-dienolide (4), 3alpha,14alpha,15beta-trihydroxy-bufa-20, 22-dienolide (5) and 3-epi-15beta-hydroxy-bufalin (6). Among them, 4-6 are novel compounds, and compound 3 is a major transformed product. The cytotoxicities of the compounds against Bel-7402 and Hela cells were investigated, and our result suggested that 14,15-OH configuration was directly related to the cytotoxicities of bufadienolides.

Microbial transformation of bufotalin by Alternaria alternata AS 3.4578.

The microbial transformation of a cytotoxic bufadienolide, bufotalin (1), was carried out. Three transformed products from 1 by Alternaria alternata were isolated. Their structures were characterized as 3-keto-bufotalin (2), 12 beta-hydroxyl-bufotalin (3), and 3-keto-12 beta-hydroxyl-bufotalin (4) based on the extensive NMR studies. Among them, 3 and 4 were new compounds with strong in vitro cytotoxic activities against HeLa cells.

Microbial transformation of cinobufagin by Syncephalastrum racemosum.

Microbial transformation of a cytotoxic bufadienolide, cinobufagin (1), was performed by Syncephalastrum racemosum. The six metabolites obtained were identified as 7beta-hydroxycinobufagin ( 2), 12beta-hydroxycinobufagin (3), cinobufotalin (4), 5,12beta-dihydroxycinobufagin (5), 4beta,11alpha-dihydroxycinobufagin (6), and 4beta,12alpha-dihydroxycinobufagin (7), respectively, on the basis of spectroscopic studies. Metabolites 2 and 5-7 were characterized as new compounds, and 2-7 proved to be cytotoxic against Bel-7402 human hepatoma cells.